TDP: More Vaccines!!
Join The Daily Printer! We offer daily finance/options trading newsletter to our 1000+ subscribers. Don’t miss out on the exclusive options news and educational content we provide! Join today: evotradingclub.com/dp
Nov 23, 2020
GM Set To Recall 5.9 Million Vehicles Utilizing Takata Air-Bag Inflation Devices
General Motors (NYSE: GM) agreed earlier today to recall nearly 6 million automobiles (SUV and Trucks) in order to replace potentially corrupted Takata Air-Bag inflators, an ordeal that could cost the company nearly $1 billion.
GM lawyers and lobbyists have been attempting to persuade the National Highway Traffic Safety Administration that the vehicles were safe for people to drive, however the agency denied those requests this morning.
This airbag recall from Takata has been one of the most complex and large scale recalls in modern American history, according to the NHTSA. According to the agency, the defect in the bags can cause them to deteriorate over time leading to potential explosions during crashes causing metal fragments to potentially kill the people in the vehicle.
J.P. Morgan Analysts Bullish on $NIO
NIO (NYSE: NIO) stock today is up more than 10% today (mid-day number) after smashing expectations during their earnings report last week. The electric vehicle manufacturer’s gross margins increased by 12.9% due to positive changes in regards to costs and pricing of their vehicles.
After analyzing the reports from last week, both JP Morgan (NYSE: JPM) and Citi (NYSE: C) analysts indicated that they were bullish on the stock and could see NIO selling more than 100,000 vehicles next year.
NIO executives reported that they believe the company will generate close to $935 million this quarter from an estimated 16,500–17,000 vehicle sales. A large increase from the 12,206 sold in Q3.
Annnnddddddd We’ve Got Another One
The joint research team from Oxford and AstraZeneca (NASDAQ: AZN) have just announced that their vaccine has an efficacy rate of 70.4% that is boosted up to 90% if given in two doses. While the news is not promising enough to bid up AstraZeneca’s stock significantly, it’s still another hope inducing release, nonetheless.
This, of course, is on the heels of the news that Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) are applying for emergency approval for their drug from the FDA; if granted, something like 50 million doses could be available worldwide before 2021; it’s not a lot, but it’s a start.
Quantifying the Market Special Series: Quant Trading (1/5)
There was a day when all trading was done by man; that day, however, is gone. Now, whenever you place an order into your iPhone, you’re fighting for a fill against countless computer algorithms scraping the internet in search of a quick buck. According to Investopedia, more than 60% of US volume in 2009–2010 was caused by high frequency traders; moreover, the flash crash of 2015 has been attributed to algorithms, as well.
While “Quant Trading,” as its called, has come to commonly be viewed as the direction in which the industry is headed, two of the most significant groups of quant funds, Renaissance and Two Sigma, have seen historic losses this year. So, the questions we’re tackling for you this week are two fold: what even is quant trading, and does the future of the market lay in its hands?
Putting a Price on the Future Education
Last week, we briefly talked about the deal hunting value investors; of course, we also have to mention the school of thought on the other end of the spectrum, the growth investors.
Growth investors look for companies that they believe will continue to have rapid appreciation in revenue, even if they haven’t yet turned a profit. The name of the game here is speculation on the future rather than crutching on the past. Growth investors are willing to take a risk to get paid in the event that they really do have an accurate idea of the future.
You can learn more by chatting with our analysts by clicking here to join our server with a free trial.
Read our newsletter disclaimer: here
